Back to results
CompletedPhase 1

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

NCT02031198

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik

Salzburg, State of Salzburg, Austria

+3 additional locations

View on ClinicalTrials.gov
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease — TrialFind